Adlai Nortye Group Ltd ADR(ANL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.54 | Insider Own | 9.15% | Shs Outstand | 58.7M | Perf Week | -9.41% |
| Market Cap | 0.60B | Forward P/E | - | EPS next Y | -59.69% | Insider Trans | -0.5% | Shs Float | 53.4M | Perf Month | -34.82% |
| Enterprise Value | 0.39B | PEG | - | EPS next Q | 0.01 | Inst Own | 36% | Short Float | 9.54% | Perf Quarter | -21.54% |
| Income | -0.02B | P/S | 33.1 | EPS this Y | 50.19% | Inst Trans | 28.2% | Short Ratio | 23.77 | Perf Half Y | -27.61% |
| Sales | 0.02B | P/B | 3.06 | EPS next 5Y | -0.26% | ROA | -14.1% | Short Interest | 5.09M | Perf YTD | 618.31% |
| Book/sh | 3.34 | P/C | 2.57 | EPS past 3/5Y | 14.75% 10.5% | ROE | -20.28% | 52W High | -40.87% ($17.25) | Perf Year | 575.5% |
| Cash/sh | 3.97 | P/FCF | - | Sales past 3/5Y | - | ROIC | -10.12% | 52W Low | 1060.94% ($0.88) | Perf 3Y | 25.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 6.08% 9.76% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 21.7 | Sales Y/Y TTM | - | Oper. Margin | -133.92% | ATR (14) | 1.1 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.55 | EPS Q/Q | - | Profit Margin | -124.82% | RSI (14) | 34.19 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.55 | Sales Q/Q | - | SMA20 | -18.54% ($12.52) | Beta | 1.19 | Target Price | $29.5 |
| Payout | - | Debt/Eq | 0.12 | Earnings | 2026/8/14 | SMA50 | -27.04% ($13.98) | Rel Volume | 0.59 | Prev Close | $10.71 |
| Employees | 109 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 9.45% 14.47% | SMA200 | -9.79% ($11.31) | Avg Volume(3M) | 0.21M | Price | $10.2 |
| IPO | 2023/9/29 | Option/Short | No/Yes | Trades | 927 | Volume | 125,339 | Change | -4.76% |
🧬 Adlai Nortye is a global clinical-stage biotech company focused on developing innovative oncology therapeutics. The company researches a broad range of targeted and immuno-oncology agents across its pipeline and continues to steadily demonstrate clinical data in global markets.
Over the past 1 year, roughly in the middle
41% below its 1-year high.
Traded less than usual. That is 59% of its average volume.
ANL has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +50.2% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,310. Peers typically go for $1,237.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be +25.6%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 36.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
BBC Virtus Biotech Clinical Trials ETF <0.01% 
CANC Tema Oncology ETF <0.01% It ranks #205 of 594 in the industry
Based on market cap of $599M.
ZVRA#202 Zevra Therapeutics Inc $612M PER 11.1 
NGNE#203 Neurogene Inc $609M PER - 
NVCT#204 Nuvectis Pharma Inc $599M PER - ANL#205 Adlai Nortye Group Ltd ADR $599M PER - 
ACRS#206 Aclaris Therapeutics Inc $583M PER - 
FAQ
What kind of company is ANL?
ANL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ANL?
The market cap of ANL is approximately $599M, ranking 3,005 within its sector.
What is the 52-week high and low for ANL?
ANL has recorded a 52-week high of $17.25 and a low of $0.88.
